About Sarcalumenin
Sarcalumenin (SRL) is a protein
from Homo sapiens identified by UniProt accession
Q86TD4, 473 residues long.
MolForge cross-references it against 0 known binders and
66 disease associations.
Target properties
| Protein name | Sarcalumenin |
|---|
| UniProt accession | Q86TD4 |
|---|
| Gene | SRL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 473 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (66)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.37
- HbA1c measurement · score 0.35
- Varicose veins · score 0.31
- neurodegenerative disease · score 0.27
- testosterone measurement · score 0.25
- diet measurement · score 0.24
- erythrocyte count · score 0.23
- pulse pressure measurement · score 0.22
- mean corpuscular volume · score 0.22
- PR interval · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86TD4-F1 | alphafold | PREDICTED | 84.21 | — |
Amino-acid sequence (473 residues)
MRALVLLGCL LASLLFSGQA EETEDANEEA PLRDRSHIEK TLMLNEDKPS DDYSAVLQRL RKIYHSSIKP LEQSYKYNEL RQHEITDGEI TSKPMVLFLG PWSVGKSTMI NYLLGLENTR YQLYTGAEPT TSEFTVLMHG PKLKTIEGIV MAADSARSFS PLEKFGQNFL EKLIGIEVPH KLLERVTFVD TPGIIENRKQ QERGYPFNDV CQWFIDRADL IFVVFDPTKL DVGLELEMLF RQLKGRESQI RIILNKADNL ATQMLMRVYG ALFWSLAPLI NVTEPPRVYV SSFWPQEYKP DTHQELFLQE EISLLEDLNQ VIENRLENKI AFIRQHAIRV RIHALLVDRY LQTYKDKMTF FSDGELVFKD IVEDPDKFYI FKTILAKTNV SKFDLPNREA YKDFFGINPI SSFKLLSQQC SYMGGCFLEK IERAITQELP GLLGSLGLGK NPGALNCDKT GCSETPKNRY RKH
Explore Sarcalumenin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets